Resources

March 16, 2022 – Legislative Update

Cerus Encouraged by the NDAA FY2022 Consideration of PR Resuscitative Products for Clinical Guidelines to Treat Obstetric Hemorrhage

Sept 20, 2021 – Press Release

Cerus Corporation Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM Virtual Annual Meeting 2021

Aug 20, 2021 – Announcement

First Patient Treated with
INTERCEPT Fibrinogen Complex

Aug 10, 2021 – Press Release

Cerus Corporation Announces CMS Issuance of P-Codes for Hospital Outpatient Billing of INTERCEPT-Based Therapeutic Products

Aug 3, 2021 – Press Release

Cerus Corporation Announces CMS Has Granted New Technology Add-On Payment for INTERCEPT Fibrinogen Complex

Nov 30, 2020 – Press Release

Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation

Oct 31, 2020 – Press Release

Emergency Medical Response Team

Cerus Receives FDA Breakthrough Device Designation for Pathogen-Reduced Cryoprecipitate

INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:

INDICATIONS FOR USE

• Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
• Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
• Second-line therapy for von Willebrand disease (vWD).
• Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII.

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.